Evolus (NASDAQ:EOLS) Sets New 1-Year High at $15.46

Evolus, Inc. (NASDAQ:EOLS) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $15.46 and last traded at $15.24, with a volume of 352269 shares changing hands. The stock had previously closed at $14.74.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on EOLS. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, August 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research report on Thursday, June 20th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Evolus in a report on Thursday, August 1st.

Evolus Stock Up 2.5 %

The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.96. The firm has a 50-day simple moving average of $12.20 and a two-hundred day simple moving average of $12.81. The company has a market cap of $992.84 million, a PE ratio of -14.74 and a beta of 1.29.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to the consensus estimate of $65.06 million. Research analysts anticipate that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 155,278 shares of Evolus stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $12.92, for a total value of $2,006,191.76. Following the transaction, the insider now owns 533,349 shares in the company, valued at $6,890,869.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Vikram Malik sold 7,500 shares of Evolus stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $12.96, for a total value of $97,200.00. Following the transaction, the director now owns 246,514 shares in the company, valued at $3,194,821.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Moatazedi sold 155,278 shares of Evolus stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $12.92, for a total value of $2,006,191.76. Following the completion of the transaction, the insider now owns 533,349 shares in the company, valued at approximately $6,890,869.08. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Evolus by 31.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,056 shares of the company’s stock worth $211,000 after acquiring an additional 4,803 shares during the last quarter. Semanteon Capital Management LP purchased a new stake in shares of Evolus during the fourth quarter worth about $472,000. AJOVista LLC purchased a new stake in shares of Evolus during the fourth quarter worth about $70,000. BNP Paribas Financial Markets increased its position in shares of Evolus by 137.4% during the fourth quarter. BNP Paribas Financial Markets now owns 220,399 shares of the company’s stock worth $2,321,000 after acquiring an additional 127,541 shares during the last quarter. Finally, Jump Financial LLC increased its position in shares of Evolus by 79.0% during the fourth quarter. Jump Financial LLC now owns 69,803 shares of the company’s stock worth $735,000 after acquiring an additional 30,797 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.